pharmaphorum

JANUARY 31, 2022

Daiichi Sankyo has stepped up its efforts to bring a Japanese COVID-19 vaccine to patients, starting a new clinical trial of its mRNA-based candidate DS-5670 that focuses on its use as a booster dose. The post Daiichi makes play for share of Japan’s COVID booster market appeared first on.

Marketing 96

Marketing Vaccination Vaccine Antibody 96

Roots Analysis

FEBRUARY 27, 2024

On November 1, 2019, Avacta Group and ADC Therapeutics have announced a collaboration agreement for the development of novel drug candidates. The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

Pharmaceutical Technology

MARCH 2, 2023

Rituximab biosimilar is under clinical development by Dr. Reddy’s Laboratories and currently in Phase III for Rheumatoid Arthritis. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Production 100

Production DNA Clinical Trials Clinical Trials 100

Drug Discovery World

MARCH 7, 2024

The combined entity will operate as Akari Therapeutics, which is expected to continue to be listed and trade on the Nasdaq Capital Market as AKTX. Following closing, the company will have an expanded pipeline that contains multiple assets spanning early and late development stages.

Antibody 59

Antibody Drugs Clinical Trials Clinical Trials 59

The Pharma Data

JANUARY 10, 2021

Because ASLAN004 is the only clinical stage monoclonal antibody targeting IL-13R?1, ASLAN004 is a first-in-class monoclonal antibody that binds to the IL-13 receptor ?1 1, we believe it has the potential to be best-in-disease which may result in improved safety and efficacy over other biologics in the class. 1 subunit (IL-13R?1),

Clinical Trials 52

Clinical Trials Clinical Trials Trials Containment 52

XTalks

JULY 17, 2023

In a significant development, Astellas Pharma announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) had accepted their applications for Priority Review and Marketing Authorization respectively for zolbetuximab. In both trials, approximately 38 percent of the screened patients had CLDN18.2-positive

Clinical Trials 95

Clinical Trials Clinical Trials Trials Antibody 95

The Pharma Data

NOVEMBER 29, 2020

Prior to joining Gannex, Dr. Palmer was Head of Liver Disease Clinical Development at Takeda Pharmaceuticals. She has also held senior leadership positions at Shire Pharmaceuticals and Kadmon Corporation, where she was in charge of the global development of NASH and other liver disease programs. ” About Ascletis.

Clinical Development 40

Clinical Development Development Clinical Trials Clinical Trials 40

Pharmaceutical Technology

FEBRUARY 19, 2023

Danburstotug is under clinical development by Sorrento Therapeutics and currently in Phase III for Cervical Cancer. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Clinical Trials 100

Clinical Trials Clinical Trials Drugs Development 100

pharmaphorum

JANUARY 13, 2022

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson’s disease, licensing a bispecific antibody from South Korea’s ABL Bio in a deal that could be worth more than $1 billion. Despite the interest, there have already been some failures in the alpha-synuclein category.

Antibody 98

Antibody Drugs Protein Licensing 98

Pharmaceutical Technology

MARCH 23, 2023

Pfizer recently announced an agreement to acquire Seagen, a biotech company based in the US with four marketed oncology therapeutic agents and a rich pipeline. Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio.

Licensing 147

Licensing Licensing Sales Trials 147

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Neuroendocrine Tumors. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

JUNE 6, 2023

XB-002 is a monoclonal antibody conjugated commercialized by Exelixis, with a leading Phase I program in Esophageal Squamous Cell Carcinoma (ESCC). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. The drug candidate is a second generation antibody drug conjugate.

Antibody 100

Antibody Development Clinical Trials Clinical Trials 100

pharmaphorum

MARCH 15, 2022

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development. Sanofi has partnered with drug delivery specialist Enable Injections to develop the subcutaneous formulation.

Trials 97

Trials Sales Drug Delivery Antibody 97

The Pharma Data

NOVEMBER 10, 2020

The NCT03763149 study is a phase 1a clinical study evaluating the tolerability, safety, and PK/PD properties of IBI188 (letaplimab) as monotherapy for advanced malignancies that failed in standard treatments. Letaplimab developed by Innovent Biologics, is a recombinant fully humanized IgG4 monoclonal antibody targeting CD47.

Antibody 52

Antibody Clinical Trials Clinical Trials Manufacturing 52

The Pharma Data

DECEMBER 29, 2020

As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. Regeneron Pharmaceuticals, Inc. futility analysis). log 10 copies/mL for combined doses).

Antibody 52

Antibody Trials Production Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 18, 2023

Gevokizumab is a monoclonal antibody commercialized by Novartis, with a leading Phase I program in Metastatic Renal Cell Carcinoma. According to Globaldata, it is involved in 34 clinical trials, of which 20 were completed, 1 is ongoing, and 13 were terminated.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

The Pharma Data

JUNE 25, 2021

protofibril antibody for the treatment of Alzheimer’s disease (AD). Breakthrough Therapy designation is an FDA program intended to expedite the development and review of medicines for serious or life-threatening conditions. You should not place undue reliance on these statements or the scientific data presented.

Antibody 40

Antibody Clinical Trials Clinical Trials Development 40

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , Yancopoulos , M.D.,

Antibody 52

Antibody Medicine Production Trials 52

Delveinsight

AUGUST 17, 2020

The Gastroparesis market size in the 7MM was found to be USD 3,170.01 million in 2019 and is anticipated to increase at a CAGR for the study period 2017-2030 owing to dynamic pipeline therapies in the mid-/ late-stage clinical development and rising gastroparesis prevalence.

Marketing 54

Marketing FDA Approval Trials Clinical Development 54

pharmaphorum

DECEMBER 21, 2021

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene. A month earlier, Bristol-Myers Squibb paid $200 million upfront for rights to a TIGIT drug developed by Agenus called AGEN1777 in a deal that could be worth up to $1.56

Drugs 98

Drugs Antibody Pharma Companies Development 98

Delveinsight

DECEMBER 1, 2020

BASE10 Collaborates with DNA Link for COVID-19 Antibody Test Research. US-based BASE10 Genetics and Korean firm DNA Link announced a collaboration on a research project to appraise the usability of the DNA Link’s antibody test, AccuFind COVID-19 IgG, in a healthcare setting. CABOMETYX is already approved in the U.S.

Antibody 52

Antibody DNA Clinical Trials Clinical Trials 52

pharmaphorum

NOVEMBER 6, 2020

Known as MSD outside North America, the big pharma already has a firm foothold in cancer thanks to its immunotherapy Keytruda (pembrolizumab), which has been on the market for several years and has proven to be effective across a wide range of oncology indications. billion in cash. The transaction is expected to close at the end of 2020.

Antibody 85

Antibody Hormones Trials Clinical Trials 85

Drug Discovery World

FEBRUARY 12, 2024

“In the upcoming year, we will see the expansion of new, more complex markets and updated requirements from regulators. Without fixing the current, broken PV models, the continuous cycle of more complexity in the market, which then pushes organisations to incorporate automation into insufficient processes, will massively hinder PV operations.

Genome 139

Genome Genomics Life Science Gene Therapy 139

pharmaphorum

DECEMBER 4, 2020

Exelixis has taken a $20 million option to license in an antibody-drug conjugate cancer (ADC) drug from Iconic, with clinical trials expected to start next year. After taking the option Exelixis now has responsibility for clinical development, marketing and manufacturing of the Tissue Factor (TF) targeting drug known as XB002.

Licensing 40

Licensing Licensing Clinical Trials Clinical Trials 40

pharmaphorum

AUGUST 1, 2022

Marengo’s approach to TCR therapy involves binding to subsets of T cells using antibodies directed at V? Thereafter, Ipsen will take responsibility for all further clinical development and commercial activities if they reach the market. The French pharma group has also promised around $1.6

Antibody 52

Antibody Clinical Trials Clinical Trials Development 52

The Pharma Data

OCTOBER 28, 2020

NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. Senior Vice President and Head of Global Clinical Development at Regeneron.

Antibody 40

Antibody Trials Production Clinical Trials 40

The Pharma Data

NOVEMBER 10, 2020

First Ever Study with take-home capsules of Foralumab , a Fully Human Anti-CD3 Monoclonal Antibody. Crohn’s Disease Therapeutics Market Size $4.7 Phase1b/2 clinical study to be conducted in the United States and several European countries. The CD therapeutic market size will be worth $4.7 Shailubhai, K.,

Life Science 40

Life Science Clinical Trials Clinical Trials Trials 40

The Pharma Data

OCTOBER 14, 2020

a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced today that the U.S. APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. SAN CARLOS, Calif. , About APX005M. About Apexigen.

Immune Response 40

Immune Response Drugs Antibody Clinical Trials 40

pharmaphorum

NOVEMBER 10, 2021

It is competing in the US with rival oral CGRPs, namely AbbVie’s Qulipta (atogepant) which was approved for episodic migraine prevention in September and AbbVie’s Ubrelvy (ubrogepant) in the acute treatment category, as well as several CGRP-targeting antibodies delivered by injection or infusion from Amgen, Eli Lilly, Teva and Lundbeck.

Licensing 52

Licensing Licensing Drugs Sales 52

XTalks

DECEMBER 10, 2021

Zavegepant is an antibody drug that prevents binding of the calcitonin gene-related peptide (CGRP) to the CGRP receptor. CGRP receptor antagonists are a new class of antibody drugs used for migraine treatment. The trial has enrolled over 1,400 adult participants with a history of migraines.

FDA Approval 98

FDA Approval Trials Drugs Sales 98

pharmaphorum

NOVEMBER 9, 2020

Swedish biotech Calliditas has announced plans to file its rare disease drug Nefecon with the FDA early next year following positive results from a phase 3 clinical trial. The antibodies produced as a result lodge in the kidneys, causing severe complications.

Drugs 52

Drugs Clinical Trials Clinical Trials Trials 52

The Pharma Data

JANUARY 10, 2021

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / January 11, 2021 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today that Jean-Paul Kress, M.D., In July 2020, the U.S.

Containment 52

Containment Clinical Development Antibody Development 52

pharmaphorum

SEPTEMBER 26, 2022

Other drugs used to treat ATL include Kyowa Kirin’s amti-CCR4 antibody Poteligeo (mogamulizumab), cleared by the MHLW for CCR4-positive ATL in 2012, as well as Bristol-Myers Squibb/Celgene’s oral therapy Revlimid (lenalidomide), which got a green light there five years ago.

Drugs 98

Drugs Clinical Trials Clinical Trials Clinical Development 98

The Pharma Data

DECEMBER 5, 2020

Potentially registrational Phase 2 portion of the trial has been initiated and is enrolling patients. NASDAQ: REGN) today announced updated data for REGN5458, a BCMAxCD3 bispecific antibody, from the Phase 1 portion of a Phase 1/2 trial in patients with relapsed or refractory (R/R) multiple myeloma.

Antibody 40

Antibody Production Trials Medicine 40

pharmaphorum

APRIL 7, 2021

Under the leadership of CEO Jan van de Winkel it has gone from financially precarious position following the stock market crash in the late noughties, to the darling of the Nasdaq with a US IPO of more than $500 million in 2019. The last ten years has seen Denmark’s Genmab become one of biotech’s big success stories.

Antibody 91

Antibody Life Science Development Regulation 91

The Pharma Data

DECEMBER 13, 2020

Margetuximab is an investigational, Fc-engineered, monoclonal antibody targeting HER2. About 15 to 20% of breast cancers cases are HER2+, and antibody-based therapies targeting HER2 have significantly improved outcomes of patients with HER2+ breast cancer. Zai Lab is leading clinical development in its territory. “We

Antibody 52

Antibody Clinical Trials Clinical Trials Licensing 52